Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (Pedvaxhib)
Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) is an FDA-licensed reference biologic from Merck Sharp & Dohme LLC. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
1989
Reference approved
Reference product
Pedvaxhib Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)
Merck Sharp & Dohme LLC
- Approved
- Dec 20, 1989
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate), in chronological order.
Reference approval
Approval date of the reference Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) product.
37 yr ago
Frequently asked questions
Are there biosimilars approved for Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) (Pedvaxhib)?
No 351(k) biosimilars or interchangeable biosimilars referencing Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.